{"protocolSection":{"identificationModule":{"nctId":"NCT03829319","orgStudyIdInfo":{"id":"7902-006"},"secondaryIdInfos":[{"id":"MK-7902-006","type":"OTHER","domain":"MSD Protocol Number"},{"id":"E7080-G000-315","type":"OTHER","domain":"Eisai Protocol Number"},{"id":"LEAP-006","type":"OTHER","domain":"MSD"},{"id":"194658","type":"REGISTRY","domain":"JAPIC-CTI"},{"id":"2018-003824-35","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)","officialTitle":"A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-03-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-08-11","type":"ACTUAL"},"completionDateStruct":{"date":"2024-08-30","type":"ACTUAL"},"studyFirstSubmitDate":"2019-02-01","studyFirstSubmitQcDate":"2019-02-01","studyFirstPostDateStruct":{"date":"2019-02-04","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-08-09","resultsFirstSubmitQcDate":"2025-02-03","resultsFirstPostDateStruct":{"date":"2025-02-21","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-11","lastUpdatePostDateStruct":{"date":"2025-09-23","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"collaborators":[{"name":"Eisai Inc.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic nonsquamous non-small cell lung cancer.\n\nThe primary study hypotheses state that: 1) the combination of lenvatinib + platinum doublet chemotherapy + pembrolizumab prolongs Progression-free Survival (PFS) as assessed by blinded independent central review (BICR) per modified Response Evaluation Criteria in Solid Tumors version 1.1 (RESIST 1.1) compared to matching placebo + platinum doublet chemotherapy + pembrolizumab, and 2) the combination of lenvatinib + platinum doublet chemotherapy + pembrolizumab prolongs Overall Survival (OS) compared to matching placebo + platinum doublet chemotherapy + pembrolizumab."},"conditionsModule":{"conditions":["Nonsquamous Non-small Cell Lung Cancer"],"keywords":["programmed cell death 1 (PD-1, PD1)","programmed cell death-ligand 1 (PD-L1, PDL1)","programmed cell death-ligand 2 (PD-L2, PDL2)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":761,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","type":"EXPERIMENTAL","description":"Participants receive carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib via oral capsule once daily.","interventionNames":["Biological: Pembrolizumab","Drug: Carboplatin","Drug: Cisplatin","Drug: Pemetrexed","Drug: Lenvatinib"]},{"label":"Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo","type":"PLACEBO_COMPARATOR","description":"In Parts 1 and 2: Participants receive carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS (Part 2 only) placebo matching lenvatinib via oral capsule once daily.","interventionNames":["Biological: Pembrolizumab","Drug: Carboplatin","Drug: Cisplatin","Drug: Pemetrexed","Drug: Placebo matching lenvatinib"]}],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab","description":"IV infusion Q3W","armGroupLabels":["Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo"],"otherNames":["MK-3475"]},{"type":"DRUG","name":"Carboplatin","description":"IV infusion Q3W","armGroupLabels":["Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo"]},{"type":"DRUG","name":"Cisplatin","description":"IV infusion Q3W","armGroupLabels":["Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo"]},{"type":"DRUG","name":"Pemetrexed","description":"IV infusion Q3W","armGroupLabels":["Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib","Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo"]},{"type":"DRUG","name":"Lenvatinib","description":"Oral capsule once daily","armGroupLabels":["Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Lenvatinib"],"otherNames":["MK-7902","E7080"]},{"type":"DRUG","name":"Placebo matching lenvatinib","description":"Oral capsule once daily","armGroupLabels":["Pemetrexed+Platinum Chemotherapy+Pembrolizumab+Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part 1: Number of Participants With a Dose-limiting Toxicity (DLT)","description":"Dose-limiting toxicity using Common Terminology Criteria for Adverse Events v4.0 for grading, is defined as any of the following hematologic toxicities: 1) Grade 4 neutropenia, 2) Grade 3 or 4 febrile neutropenia, 3) thrombocytopenia \\<25,000 cells/mm\\^3 associated with bleeding and/or which requires platelet transfusion, or any of the following non-hematologic toxicities: 4) any other Grade 4 or 5 toxicity, 5) Grade 3 toxicities lasting \\>3 days (exclusions apply), 6) Grade 3 hypertension not controlled by medication, 7) Grade 3 or above gastrointestinal perforation, 8) Grade 3 or above wound dehiscence requiring medical or surgical intervention, 9) any grade thromboembolic event, or 10) any Grade 3 nonhematologic laboratory value if medical intervention is required or the abnormality leads to hospitalization.","timeFrame":"Cycle 1; each cycle is 21 days (up to 21 days)"},{"measure":"Part 1: Number of Participants Who Experienced an Adverse Event (AE)","description":"An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one of more adverse events during Part 1 of this study will be presented.","timeFrame":"Up to approximately 48 months"},{"measure":"Part 1: Number of Participants Who Discontinued Study Drug Due to an Adverse Event","description":"An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study medication due to and adverse event during Part 1 of this study will be presented.","timeFrame":"Up to approximately 58 months"},{"measure":"Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"PFS was defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. Data are from the product-limit (Kaplan-Meier) method for censored data. PFS as assessed by blinded independent central review (BICR) per RECIST 1.1 is presented.","timeFrame":"Up to approximately 36 months"},{"measure":"Part 2: Overall Survival (OS)","description":"OS is defined as the time from randomization to the time of death from any cause. OS is presented.","timeFrame":"Up to approximately 47 months"}],"secondaryOutcomes":[{"measure":"Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. ORR as assessed per modified RECIST 1.1 will be presented.","timeFrame":"Up to approximately 19 months"},{"measure":"Part 2: Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"For participants who demonstrated CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the time from the first documented evidence of CR or PR until PD or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, or death from any cause, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. DOR as assessed per modified RECIST 1.1 will be presented.","timeFrame":"Up to approximately 48 months"},{"measure":"Part 2: Number of Participants Who Experienced an Adverse Event (AE)","description":"An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced one of more adverse events during Part 2 of this study were presented.","timeFrame":"Up to approximately 58 months"},{"measure":"Part 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event","description":"An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment during Part 2 of this study were presented.","timeFrame":"Up to approximately 58 months"},{"measure":"Part 2: Change From Baseline in Global Health Status (GHS) (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 [EORTC QLQ-C30] Items 29 and 30) Score","description":"The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions regarding Global Health Status (GHS; \"How would you rate your overall health during the past week?\") and Quality of Life (QoL; \"How would you rate your overall quality of life during the past week?\") are each scored on a 7-point scale (1=Very poor to 7=Excellent). The two raw scores were averaged into a combined score, then normalized using linear transformation so each participant's score ranged from 0 to 100 (0=Worst overall health/quality of life and 100=Best overall health/quality of life). The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QoL (EORTC QLQ-C30 Item 30) combined score is presented","timeFrame":"Baseline and Week 27"},{"measure":"Part 2: Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score","description":"The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question \"How much did you cough?\" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in cough (EORTC QLQ-LC13 Item 31) score will be presented. A lower score indicates a better outcome.","timeFrame":"Baseline and week 27"},{"measure":"Part 2: Change From Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score","description":"The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question \"Have you had pain in your chest?\" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in chest pain (EORTC QLQ-LC13 Item 40) score will be presented. A lower score indicates a better outcome.","timeFrame":"Baseline and Week 27"},{"measure":"Part 2: Change From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score","description":"The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the question \"Were you short of breath?\" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in dyspnea (EORTC QLQ-C30 Item 8) score will be presented. A lower score indicates a better outcome.","timeFrame":"Baseline and Week 27"},{"measure":"Part 2: Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score","description":"The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score will be presented. A higher score indicates a better quality of life.","timeFrame":"Baseline and Week 27"},{"measure":"Part 2: Time to True Deterioration (TTD) Based on Change From Baseline in Global Health Status (GHS)/Quality of Life (QoL) (EORTC QLQ-C30 Items 29 and 30) Score","description":"TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in GHS/QoL (EORTC QLQ-C30 Items 29 and 30) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from Baseline in GHS/QoL score, will be presented. A longer TTD indicates a better outcome.","timeFrame":"Baseline and Week 27"},{"measure":"Part 2: TTD Based on Change From Baseline in Cough EORTC QLQ-LC13 (Item 31) Score","description":"TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline cough (EORTC QLQ-LC30 Items 31) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from Baseline in physical functioning score, will be presented. A longer TTD indicates a better outcome.","timeFrame":"Baseline And Week 27"},{"measure":"Part 2: TTD Based on Change From Baseline in Chest Pain EORTC QLQ-LC13 (Item 40) Score","description":"TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline chest pain (EORTC QLQ-C30 Item 40) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from Baseline in chest pains core, will be presented. A longer TTD indicates a better outcome.","timeFrame":"Baseline and Week 27"},{"measure":"Part 2: TTD Based on Change From Baseline in Dyspnea EORTC QLQ-C30 (Item 8) Score","description":"TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline dyspnea (EORTC QLQ-C30 Item 8) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from Baseline in dyspnea score, will be presented. A longer TTD indicates a better outcome.","timeFrame":"Baseline and Week 27"},{"measure":"Part 2: TTD Based on Change From Baseline in Physical Functioning EORTC QLQ-C30 (Items 1 Through 5) Score","description":"TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline physical functioning (EORTC QLQ-C30 Items 1 through 5) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from Baseline in physical functioning score, will be presented. A longer TTD indicates a better outcome.","timeFrame":"Baseline and Week 27"},{"measure":"Part 2: Time to True Deterioration (TTD) Based on Change From Baseline in the Composite Endpoint of Cough (EORTC QLQ-LC13 Item 31), Chest Pain (EORTC QLQ-LC13 Item 40), or Dyspnea (EORTC QLQ-C30 Item 8)","description":"TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in the composite endpoint of cough (QLQ-LC13 item 31), chest pain (QLQ-LC13 item 40), or dyspnea (QLQ-C30 Item 8). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from Baseline in the composite endpoint of cough, chest pain or dyspnea, will be presented. A longer TTD indicates a better outcome.","timeFrame":"Baseline and Week 27"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of Stage IV (American Joint Committee on Cancer \\[AJCC\\], version 8 or current version), nonsquamous NSCLC.\n* Confirmation that Epidermal Growth Factor Receptor (EGFR), ALK Receptor Tyrosine Kinase (ALK), or ROS1 Receptor Tyrosine Kinase (ROS1)-directed therapy is not indicated as primary treatment (documentation of absence of tumor-activating EGFR mutations AND absence of ALK and ROS1 gene rearrangements OR presence of a Kirsten Rat Sarcoma (KRAS) gene mutation).\n* Have measurable disease based on RECIST 1.1. Note: Lesions that appear measurable, but are situated in a previously irradiated area, can be considered measurable (eligible for selection as target lesions) if they have shown documented growth since the completion of radiation.\n* Provided an archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion (not previously irradiated).\n* Life expectancy of at least 3 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to the first dose of study intervention but before randomization.\n* Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirements above, the local label requirements are to be followed.\n* Male participants must agree for at least 7 days after the last dose of lenvatinib/matching placebo and up to 180 days after the last dose of chemotherapeutic agents to:\n\n  1. Refrain from donating sperm PLUS either:\n  2. Be abstinence from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR\n  3. Must agree to use contraception unless confirmed to be azoopsermic (vasectomized or secondary to medical cause) as detailed below:\n\n     1. Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a woman of childbearing potential (WOCBP) who is not currently pregnant Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from penile-vaginal intercourse or use a male condom during each episode of penile-vaginal penetration.\n\nNote: 7 days after lenvatinib/matching placebo is stopped, if the participant is on pembrolizumab only and is greater than 180 days post chemotherapy, no male contraception measures are needed.\n\n* Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n* Female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:\n\n  1. Is not a WOCBP OR\n  2. Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\<1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis), during the intervention period and for at least 120 days post pembrolizumab and/or 30 days post-lenvatinib/matching placebo, and up to 180 days post last dose of chemotherapeutic agents, whichever occurs last.\n* Adequate organ function.\n* Adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP ≤150/90 mm Hg and no change in antihypertensive medications within 1 week prior to randomization. Note: Participants must not have a history of uncontrolled or poorly-controlled hypertension, defined as \\>150/90 mm Hg for \\>4 weeks despite standard medical management.\n\nExclusion Criteria:\n\n* Known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, clinically stable, and have not required steroids for at least 14 days prior to the first dose of study intervention.\n* History of (noninfectious) pneumonitis that required systemic steroids or current pneumonitis/interstitial lung disease.\n* Radiographic evidence of intratumoral caviations, encasement, or invasion of a major blood vessel. Additionally, the degree of proximity to major blood vessels should be considered for exclusion because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis after lenvatinib-therapy. (In the chest, major blood vessels include the main pulmonary artery, the left and right pulmonary arteries, the 4 major pulmonary veins, the superior or inferior vena cava, and the aorta).\n* Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy. Note: The time requirement also does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers.\n* Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is allowed.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention.\n* Has had allogeneic tissue/solid organ transplant.\n* Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by the local health authority.\n* Known history of Hepatitis B or active Hepatitis C. No testing for Hepatitis B or Hepatitis C is required unless mandated by the local health authority.\n* History of a gastrointestinal condition or procedure that in the opinion of the investigator may affect oral drug absorption.\n* Active hemoptysis (at least 0.5 teaspoon of bright red blood) within 2 weeks prior to the first dose of study intervention.\n* Significant cardiovascular impairment within 12 months prior to the first dose of study intervention, including history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction, cerebrovascular accident (CVA)/stroke, or cardiac arrhythmia associated with hemodynamic instability.\n* Known history of active tuberculosis.\n* Active infection requiring systemic therapy.\n* Has not recovered adequately from any toxicity and/or complication from major surgery prior to the first dose of study intervention.\n* Previously had a severe hypersensitivity reaction to treatment with a monoclonal antibody or has a known sensitivity to any component of lenvatinib or pembrolizumab, or as applicable, carboplatin, cisplatin, or pemetrexed.\n* A WOCBP who has a positive urine pregnancy test within 24 hours prior to randomization or treatment allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula.\n* Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic NSCLC.\n* Received prior treatment with pembrolizumab or any other anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2 agent, with lenvatinib or any other receptor tyrosine kinase inhibitor (RTKi), or with an agent directed to another stimulatory or co-inhibitory T cell receptor.\n* Received radiotherapy within 14 days prior to the first dose of study intervention or received lung radiation therapy of \\>30 Gy within 6 months prior to the first dose of study intervention. Note: Participants must have recovered from all radiation-related toxicities to Grade ≤1, not required corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.\n* Received systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) within 7 days prior to the first dose of study intervention.\n* Received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention. Note: killed vaccines are allowed.\n* Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study intervention.\n* Has a prolongation of QTc interval (calculated using Fridericia's formula) of \\>480 msecl.\n* Left ventricular ejection fraction (LVEF) below the institutional (or local laboratory) normal range as determined by multigated acquisition scan (MUGA) or echocardiogram (ECHO).\n* Has preexisting ≥Grade 3 gastrointestinal or non-gastrointestinal fistula","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"El Camino Hospital Cancer Center ( Site 0529)","city":"Mountain View","state":"California","zip":"94040","country":"United States","geoPoint":{"lat":37.38605,"lon":-122.08385}},{"facility":"Yale University ( Site 0519)","city":"New Haven","state":"Connecticut","zip":"06520-8028","country":"United States","geoPoint":{"lat":41.30815,"lon":-72.92816}},{"facility":"Holy Cross Hospital ( Site 0512)","city":"Fort Lauderdale","state":"Florida","zip":"33308","country":"United States","geoPoint":{"lat":26.12231,"lon":-80.14338}},{"facility":"Mercy Health-Paducah Medical Oncology and Hematology ( Site 0570)","city":"Paducah","state":"Kentucky","zip":"42003","country":"United States","geoPoint":{"lat":37.08339,"lon":-88.60005}},{"facility":"Henry Ford Health System ( Site 0563)","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Saint Lukes Cancer Institute ( Site 0541)","city":"Kansas City","state":"Missouri","zip":"64111","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Broome Oncology, LLC ( Site 0562)","city":"Johnson City","state":"New York","zip":"13790","country":"United States","geoPoint":{"lat":42.11563,"lon":-75.95881}},{"facility":"Sanford Health Roger Maris Cancer Center ( Site 0533)","city":"Fargo","state":"North Dakota","zip":"58122","country":"United States","geoPoint":{"lat":46.87719,"lon":-96.7898}},{"facility":"Stephenson Cancer Center ( Site 0504)","city":"Oklahoma City","state":"Oklahoma","zip":"73104","country":"United States","geoPoint":{"lat":35.46756,"lon":-97.51643}},{"facility":"Good Samaritan Hospital Corvallis ( Site 0521)","city":"Corvallis","state":"Oregon","zip":"97330","country":"United States","geoPoint":{"lat":44.56457,"lon":-123.26204}},{"facility":"Thomas Jefferson University Hospital ( Site 0548)","city":"Philadelphia","state":"Pennsylvania","zip":"19107","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Abington Hospital - Asplundh Cancer Center ( Site 0575)","city":"Willow Grove","state":"Pennsylvania","zip":"19090","country":"United States","geoPoint":{"lat":40.144,"lon":-75.11573}},{"facility":"West Cancer Center - East Campus ( Site 0544)","city":"Germantown","state":"Tennessee","zip":"38138","country":"United States","geoPoint":{"lat":35.08676,"lon":-89.81009}},{"facility":"Parkland Health & Hospital System ( Site 0576)","city":"Dallas","state":"Texas","zip":"75235","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"UT Southwestern Medical Center ( Site 0558)","city":"Dallas","state":"Texas","zip":"75390","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Utah Cancer Specialists ( Site 0523)","city":"Salt Lake City","state":"Utah","zip":"84106","country":"United States","geoPoint":{"lat":40.76078,"lon":-111.89105}},{"facility":"West Virginia University ( Site 0526)","city":"Morgantown","state":"West Virginia","zip":"26506","country":"United States","geoPoint":{"lat":39.62953,"lon":-79.9559}},{"facility":"Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 0367)","city":"Berazategui","state":"Buenos Aires","zip":"B1884BBF","country":"Argentina","geoPoint":{"lat":-34.76531,"lon":-58.21278}},{"facility":"Instituto de Investigaciones Clinicas Mar del Plata ( Site 0371)","city":"Mar del Plata","state":"Buenos Aires","zip":"B7600FZO","country":"Argentina","geoPoint":{"lat":-38.00042,"lon":-57.5562}},{"facility":"CEMIC ( Site 0370)","city":"Buenos Aires","state":"Buenos Aires F.D.","zip":"C1431FWO","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Sanatorio Parque ( Site 0365)","city":"Rosario","state":"Santa Fe Province","zip":"S2000DSV","country":"Argentina","geoPoint":{"lat":-32.94682,"lon":-60.63932}},{"facility":"Hospital Aleman ( Site 0368)","city":"Buenos Aires","zip":"C1118AAT","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"Instituto Medico Especializado Alexander Fleming ( Site 0369)","city":"Buenos Aires","zip":"C1426ANZ","country":"Argentina","geoPoint":{"lat":-34.61315,"lon":-58.37723}},{"facility":"CEMAIC ( Site 0374)","city":"Córdoba","zip":"X5008HHW","country":"Argentina","geoPoint":{"lat":-31.40648,"lon":-64.18853}},{"facility":"CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica ( Site 0372)","city":"San Juan","zip":"J5402DIL","country":"Argentina","geoPoint":{"lat":-31.53726,"lon":-68.52568}},{"facility":"Blacktown Hospital Western Sydney Local Health District ( Site 0008)","city":"Blacktown","state":"New South Wales","zip":"2148","country":"Australia","geoPoint":{"lat":-33.76667,"lon":150.91667}},{"facility":"Port Macquarie Base Hospital ( Site 0001)","city":"Port Macquarie","state":"New South Wales","zip":"2444","country":"Australia","geoPoint":{"lat":-31.43084,"lon":152.90894}},{"facility":"Chris OBrien Lifehouse ( Site 0006)","city":"Sydney","state":"New South Wales","zip":"2050","country":"Australia","geoPoint":{"lat":-33.86785,"lon":151.20732}},{"facility":"Westmead Hospital ( Site 0009)","city":"Sydney","state":"New South Wales","zip":"2145","country":"Australia","geoPoint":{"lat":-33.86785,"lon":151.20732}},{"facility":"Cairns Hospital ( Site 0002)","city":"Cairns","state":"Queensland","zip":"4870","country":"Australia","geoPoint":{"lat":-16.92366,"lon":145.76613}},{"facility":"The Prince Charles Hospital ( Site 0010)","city":"Chermside","state":"Queensland","zip":"4032","country":"Australia","geoPoint":{"lat":-27.38472,"lon":153.03062}},{"facility":"Ballarat Health Services ( Site 0003)","city":"Ballarat","state":"Victoria","zip":"3350","country":"Australia","geoPoint":{"lat":-37.56622,"lon":143.84957}},{"facility":"Moncton Hospital - Horizon Health Network ( Site 0410)","city":"Moncton","state":"New Brunswick","zip":"E1C 6Z8","country":"Canada","geoPoint":{"lat":46.09454,"lon":-64.7965}},{"facility":"Juravinski Cancer Centre ( Site 0407)","city":"Hamilton","state":"Ontario","zip":"L8V 1C3","country":"Canada","geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"Kingston Health Sciences Centre ( Site 0414)","city":"Kingston","state":"Ontario","zip":"K7L 2V7","country":"Canada","geoPoint":{"lat":44.22976,"lon":-76.48098}},{"facility":"Lakeridge Health ( Site 0406)","city":"Oshawa","state":"Ontario","zip":"L1G 2B9","country":"Canada","geoPoint":{"lat":43.90012,"lon":-78.84957}},{"facility":"Sault Area Hospital ( Site 0413)","city":"Sault Ste. Marie","state":"Ontario","zip":"P6B 0A8","country":"Canada","geoPoint":{"lat":46.51677,"lon":-84.33325}},{"facility":"Hopital Cite de la Sante de Laval ( Site 0400)","city":"Laval","state":"Quebec","zip":"H7M 3L9","country":"Canada","geoPoint":{"lat":45.56995,"lon":-73.692}},{"facility":"CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0412)","city":"Montreal","state":"Quebec","zip":"H3T 1M5","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0403)","city":"Québec","state":"Quebec","zip":"G1R 2J6","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"CIUSSS de la Mauricie et du Centre du Quebec ( Site 0408)","city":"Trois-Rivières","state":"Quebec","zip":"G8Z 3R9","country":"Canada","geoPoint":{"lat":46.34515,"lon":-72.5477}},{"facility":"Clinica Universidad Catolica del Maule ( Site 0385)","city":"Talca","state":"Maule Region","zip":"3465584","country":"Chile","geoPoint":{"lat":-35.4232,"lon":-71.64974}},{"facility":"OrlandiOncologia ( Site 0381)","city":"Santiago","state":"Region M. de Santiago","zip":"7500713","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Fundacion Arturo Lopez Perez FALP ( Site 0383)","city":"Santiago","state":"Region M. de Santiago","zip":"7500921","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Pontificia Universidad Catolica de Chile ( Site 0382)","city":"Santiago","state":"Region M. de Santiago","zip":"8330032","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Bradford Hill Centro de Investigaciones Clinicas ( Site 0387)","city":"Santiago","state":"Region M. de Santiago","zip":"8420383","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0380)","city":"Temuco","state":"Región de la Araucanía","zip":"4810218","country":"Chile","geoPoint":{"lat":-38.73628,"lon":-72.59738}},{"facility":"Oncocentro ( Site 0384)","city":"Viña del Mar","state":"Región de Valparaíso","zip":"2520598","country":"Chile","geoPoint":{"lat":-33.02457,"lon":-71.55183}},{"facility":"Centro Oncologico Antofagasta ( Site 0386)","city":"Antofagasta","zip":"1240000","country":"Chile","geoPoint":{"lat":-23.65094,"lon":-70.39752}},{"facility":"Peking Union Medical College Hospital ( Site 0108)","city":"Beijing","state":"Beijing Municipality","zip":"100006","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Cancer Hospital Chinese Academy of Medical Science ( Site 0117)","city":"Beijing","state":"Beijing Municipality","zip":"100021","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Beijing Cancer Hospital ( Site 0120)","city":"Beijing","state":"Beijing Municipality","zip":"100036","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"The Second Hospital Affiliated to AMU ( Site 0119)","city":"Chongqing","state":"Chongqing Municipality","zip":"400037","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"First Affiliated Hospital of The Third Military Medical University ( Site 0118)","city":"Chongqing","state":"Chongqing Municipality","zip":"400038","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"Fujian Provincial Cancer Hospital ( Site 0102)","city":"Fuzhou","state":"Fujian","zip":"350014","country":"China","geoPoint":{"lat":26.06139,"lon":119.30611}},{"facility":"Southern Medical University Nanfang Hospital ( Site 0121)","city":"Guangzhou","state":"Guangdong","zip":"510515","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"The Third Affiliated Hospital of Harbin Medical University ( Site 0100)","city":"Harbin","state":"Heilongjiang","zip":"150081","country":"China","geoPoint":{"lat":45.75,"lon":126.65}},{"facility":"Henan Cancer Hospital ( Site 0112)","city":"Zhengzhou","state":"Henan","zip":"450008","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"Wuhan Union Hospital Cancer Center-Cancer Center ( Site 0123)","city":"Wuhan","state":"Hubei","zip":"430022","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Hubei Cancer Hospital ( Site 0122)","city":"Wuhan","state":"Hubei","zip":"430079","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Jilin Cancer Hospital ( Site 0115)","city":"Changchun","state":"Jilin","zip":"130103","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Zhongshan Hospital Fudan University ( Site 0103)","city":"Shanghai","state":"Shanghai Municipality","zip":"200032","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Shanghai Pulmonary Hospital ( Site 0101)","city":"Shanghai","state":"Shanghai Municipality","zip":"200443","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Tianjin Medical University Cancer Institute & Hospital ( Site 0111)","city":"Tianjin","state":"Tianjin Municipality","zip":"300060","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}},{"facility":"Cancer Hospital Affiliated to Xinjiang Medical University ( Site 0110)","city":"Urumuqi","state":"Xinjiang","zip":"830000","country":"China"},{"facility":"The First Affiliated Hospital Zhejiang University ( Site 0109)","city":"Hangzhou","state":"Zhejiang","zip":"310003","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Zhejiang Cancer Hospital ( Site 0113)","city":"Hangzhou","state":"Zhejiang","zip":"310022","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"The First Affiliated Hospital of Wenzhou Medical University ( Site 0124)","city":"Wenzhou","state":"Zhejiang","zip":"325000","country":"China","geoPoint":{"lat":27.99942,"lon":120.66682}},{"facility":"Hopital Cardiologique Louis Pradel ( Site 0141)","city":"Bron","state":"Auvergne-Rhône-Alpes","zip":"69500","country":"France","geoPoint":{"lat":45.73865,"lon":4.91303}},{"facility":"Centre Paul Strauss ( Site 0144)","city":"Strasbourg","state":"Bas-Rhin","zip":"67065","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Hopital Nord du Marseille ( Site 0147)","city":"Marseille","state":"Bouches-du-Rhone","zip":"13015","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"facility":"Hopital Foch ( Site 0145)","city":"Suresnes","state":"Hauts-de-Seine","zip":"92151","country":"France","geoPoint":{"lat":48.87143,"lon":2.22929}},{"facility":"Centre de Cancerologie du Grand Montpellier ( Site 0142)","city":"Montpellier","state":"Herault","zip":"34070","country":"France","geoPoint":{"lat":43.61093,"lon":3.87635}},{"facility":"Hopital Laennec ( Site 0146)","city":"Nantes","state":"Loire-Atlantique","zip":"44093","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"Hopital Robert Schuman ( Site 0143)","city":"Vantoux","state":"Moselle","zip":"57070","country":"France","geoPoint":{"lat":49.12945,"lon":6.23201}},{"facility":"L'hopital Nord-Ouest - Centre Hospitalier de Villefranche sur Saone ( Site 0149)","city":"Villefranche-sur-Saône","state":"Rhone","zip":"69655","country":"France","geoPoint":{"lat":45.98967,"lon":4.71961}},{"facility":"Hopital Cochin ( Site 0140)","city":"Paris","zip":"75014","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Klinikum Esslingen GmbH ( Site 0164)","city":"Esslingen am Neckar","state":"Baden-Wurttemberg","zip":"73730","country":"Germany","geoPoint":{"lat":48.73961,"lon":9.30473}},{"facility":"Krankenhaus Nordwest ( Site 0169)","city":"Frankfurt am Main","state":"Hesse","zip":"60488","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Pius Hospital Oldenburg ( Site 0170)","city":"Oldenburg","state":"Lower Saxony","zip":"26121","country":"Germany","geoPoint":{"lat":53.14118,"lon":8.21467}},{"facility":"Uniklinik RWTH Aachen ( Site 0160)","city":"Aachen","state":"North Rhine-Westphalia","zip":"52074","country":"Germany","geoPoint":{"lat":50.77664,"lon":6.08342}},{"facility":"Universitaetsklinikum des Saarlandes ( Site 0165)","city":"Homburg","state":"Saarland","zip":"66421","country":"Germany","geoPoint":{"lat":49.32637,"lon":7.33867}},{"facility":"Krankenhaus Martha Maria Halle-Doelau ( Site 0166)","city":"Halle","state":"Saxony-Anhalt","zip":"06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"LungenClinic Grosshansdorf GmbH ( Site 0171)","city":"Großhansdorf","state":"Schleswig-Holstein","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Hamato-Onkologie Hamburg Prof. Laack und Partner ( Site 0161)","city":"Hamburg","zip":"20251","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"facility":"Soroka Medical Center ( Site 0222)","city":"Beersheba","zip":"8410101","country":"Israel","geoPoint":{"lat":31.25181,"lon":34.7913}},{"facility":"Rambam Medical Center ( Site 0223)","city":"Haifa","zip":"3109601","country":"Israel","geoPoint":{"lat":32.81303,"lon":34.99928}},{"facility":"Shaare Zedek Medical Center-Oncology ( Site 0229)","city":"Jerusalem","zip":"9013102","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Meir Medical Center ( Site 0221)","city":"Kfar Saba","zip":"4428164","country":"Israel","geoPoint":{"lat":32.175,"lon":34.90694}},{"facility":"Holy Family Hospital ( Site 0228)","city":"Nazareth","zip":"1641101","country":"Israel","geoPoint":{"lat":32.70087,"lon":35.29719}},{"facility":"Rabin Medical Center ( Site 0224)","city":"Petah Tikva","zip":"4941492","country":"Israel","geoPoint":{"lat":32.08707,"lon":34.88747}},{"facility":"Sheba Medical Center ( Site 0220)","city":"Ramat Gan","zip":"5262000","country":"Israel","geoPoint":{"lat":32.08227,"lon":34.81065}},{"facility":"Sourasky Medical Center ( Site 0225)","city":"Tel Aviv","zip":"6423906","country":"Israel","geoPoint":{"lat":32.08088,"lon":34.78057}},{"facility":"Shamir Medical Center-Assaf Harofeh ( Site 0227)","city":"Ẕerifin","zip":"70300","country":"Israel","geoPoint":{"lat":31.95731,"lon":34.84852}},{"facility":"National Hospital Organization Nagoya Medical Center ( Site 0017)","city":"Nagoya","state":"Aichi-ken","zip":"460-0001","country":"Japan","geoPoint":{"lat":35.18147,"lon":136.90641}},{"facility":"Fujita Health University Hospital ( Site 0016)","city":"Toyoake","state":"Aichi-ken","zip":"470-1192","country":"Japan","geoPoint":{"lat":35.038,"lon":136.99931}},{"facility":"National Cancer Center Hospital East ( Site 0024)","city":"Kashiwa","state":"Chiba","zip":"277-8577","country":"Japan","geoPoint":{"lat":35.86224,"lon":139.97732}},{"facility":"Kanazawa University Hospital ( Site 0018)","city":"Kanazawa","state":"Ishikawa-ken","zip":"920-8641","country":"Japan","geoPoint":{"lat":36.6,"lon":136.61667}},{"facility":"Osaka Habikino Medical Center ( Site 0020)","city":"Habikino","state":"Osaka","zip":"583-8588","country":"Japan","geoPoint":{"lat":34.55276,"lon":135.59097}},{"facility":"Kansai Medical University Hospital ( Site 0022)","city":"Hirakata","state":"Osaka","zip":"573-1191","country":"Japan","geoPoint":{"lat":34.81352,"lon":135.64914}},{"facility":"Niigata Cancer Center Hospital ( Site 0019)","city":"Niigata","zip":"951-8566","country":"Japan","geoPoint":{"lat":37.92259,"lon":139.04125}},{"facility":"National Cancer Center Hospital ( Site 0026)","city":"Tokyo","zip":"104-0045","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Tokyo Metropolitan Komagome Hospital ( Site 0015)","city":"Tokyo","zip":"113-8677","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"The Cancer Institute Hospital of JFCR ( Site 0021)","city":"Tokyo","zip":"135-8550","country":"Japan","geoPoint":{"lat":35.6895,"lon":139.69171}},{"facility":"Wakayama Medical University Hospital ( Site 0025)","city":"Wakayama","zip":"641-8510","country":"Japan","geoPoint":{"lat":34.23333,"lon":135.16667}},{"facility":"Tauranga Hospital ( Site 0004)","city":"Tauranga","state":"Bay of Plenty","zip":"3112","country":"New Zealand","geoPoint":{"lat":-37.68611,"lon":176.16667}},{"facility":"Auckland City Hospital ( Site 0011)","city":"Auckland","zip":"1023","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Pleszewskie Centrum Medyczne w Pleszewie Sp. z o.o. ( Site 0615)","city":"Pleszew","state":"Greater Poland Voivodeship","zip":"63-300","country":"Poland","geoPoint":{"lat":51.89636,"lon":17.78549}},{"facility":"MED-POLONIA Sp. z o.o. ( Site 0609)","city":"Poznan","state":"Greater Poland Voivodeship","zip":"60-693","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Centrum Onkologii im.prof. F. Lukaszczyka w Bydgoszczy ( Site 0601)","city":"Bydgoszcz","state":"Kuyavian-Pomeranian Voivodeship","zip":"85-796","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 0603)","city":"Warsaw","state":"Masovian Voivodeship","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Szpital Wojewodzki im. Mikolaja Kopernika ( Site 0602)","city":"Koszalin","state":"West Pomeranian Voivodeship","zip":"75-581","country":"Poland","geoPoint":{"lat":54.19438,"lon":16.17222}},{"facility":"Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii ( Site 0613)","city":"Lodz","state":"Łódź Voivodeship","zip":"93-513","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"Leningrad Regional Oncology Center ( Site 0271)","city":"Saint Petersburg","state":"Leningradskaya Oblast'","zip":"197758","country":"Russia"},{"facility":"City Clinical Hospital 1 na. NI. Pirogov ( Site 0270)","city":"Moscow","state":"Moscow","zip":"119049","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Central Clinical Hospital with outpatient Clinic ( Site 0262)","city":"Moscow","state":"Moscow","zip":"121359","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"National Medical Research Radiology Centre ( Site 0260)","city":"Moscow","state":"Moscow","zip":"125284","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 0264)","city":"Moscow","state":"Moscow","zip":"125367","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Moscow Regional Oncological Dispensary ( Site 0274)","city":"Balashikha","state":"Moscow Oblast","zip":"143900","country":"Russia","geoPoint":{"lat":55.79479,"lon":37.94794}},{"facility":"Nizhniy Novgorod Region Oncology Dispensary ( Site 0272)","city":"Nizhny Novgorod","state":"Nizhny Novgorod Oblast","zip":"603081","country":"Russia","geoPoint":{"lat":56.32867,"lon":44.00205}},{"facility":"Omsk Clinical Oncology Dispensary ( Site 0267)","city":"Omsk","state":"Omsk Oblast","zip":"644013","country":"Russia","geoPoint":{"lat":54.99244,"lon":73.36859}},{"facility":"First Pavlov State Medical University of Saint Petersburg-Department of Oncology ( Site 0273)","city":"Saint Petersburg","state":"Sankt-Peterburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0269)","city":"Saint Petersburg","state":"Sankt-Peterburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"SAHI Republican Clinical Oncological Dispensary of the MoH of RT ( Site 0261)","city":"Kazan'","state":"Tatarstan, Respublika","zip":"420029","country":"Russia","geoPoint":{"lat":55.78874,"lon":49.12214}},{"facility":"National Cancer Center ( Site 0061)","city":"Goyang-si","state":"Kyonggi-do","zip":"10408","country":"South Korea","geoPoint":{"lat":37.65639,"lon":126.835}},{"facility":"The Catholic University of Korea St. Vincent s Hospital ( Site 0064)","city":"Gyeonggi-do","state":"Kyonggi-do","zip":"16247","country":"South Korea","geoPoint":{"lat":37.58944,"lon":126.76917}},{"facility":"Chungbuk National University Hospital ( Site 0062)","city":"Cheongju-si","state":"North Chungcheong","zip":"28644","country":"South Korea","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"Severance Hospital Yonsei University Health System ( Site 0063)","city":"Seoul","zip":"03722","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"ICO L Hospitalet ( Site 0234)","city":"L'Hospitalet de Llobregat","state":"Barcelona","zip":"08907","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"Complejo Hospitalario Universitario A Coruna ( Site 0239)","city":"A Coruña","state":"La Coruna","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Hospital Universitario Insular de Gran Canaria ( Site 0244)","city":"Las Palmas de Gran Canaria","state":"Las Palmas","zip":"35001","country":"Spain","geoPoint":{"lat":28.10178,"lon":-15.41573}},{"facility":"Hospital General Universitario de Valencia ( Site 0231)","city":"Valencia","state":"Valenciana, Comunitat","zip":"46014","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital Universitario La Fe ( Site 0233)","city":"Valencia","state":"Valenciana, Comunitat","zip":"46026","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital General Universitario de Alicante ( Site 0240)","city":"Alicante","zip":"03010","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Hospital Santa Creu i Sant Pau ( Site 0241)","city":"Barcelona","zip":"08025","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital General Universitario Gregorio Maranon ( Site 0237)","city":"Madrid","zip":"28009","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Clinico San Carlos ( Site 0235)","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario La Paz ( Site 0236)","city":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Complejo Hospitalario de Malaga ( Site 0238)","city":"Málaga","zip":"29010","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Hospital Universitario Miguel Servet ( Site 0242)","city":"Zaragoza","zip":"50009","country":"Spain","geoPoint":{"lat":41.65606,"lon":-0.87734}},{"facility":"Cukurova Universitesi Tıp Fakultesi Balcalı Hastanesi ( Site 0314)","city":"Adana","zip":"01330","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Hacettepe Universitesi Tıp Fakultesi ( Site 0316)","city":"Ankara","zip":"06100","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Ankara Universitesi Tip Fakultesi. ( Site 0317)","city":"Ankara","zip":"06620","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Ankara Sehir Hastanesi ( Site 0323)","city":"Ankara","zip":"06800","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0312)","city":"Istanbul","zip":"34098","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0310)","city":"Istanbul","zip":"34722","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Ege Universitesi Tip Fakultesi ( Site 0313)","city":"Izmir","zip":"35100","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"facility":"Inonu Universitesi Medical Fakultesi ( Site 0318)","city":"Malatya","zip":"44280","country":"Turkey (Türkiye)","geoPoint":{"lat":38.35018,"lon":38.31667}},{"facility":"Cambridge University Hospitals NHS Trust ( Site 0293)","city":"Cambridge","state":"Cambridgeshire","zip":"CB2 0QQ","country":"United Kingdom","geoPoint":{"lat":52.2,"lon":0.11667}},{"facility":"North Middlesex University Hospital NHS Trust ( Site 0291)","city":"London","state":"London, City of","zip":"N18 1QX","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Guys and St Thomas NHS Foundation Trust ( Site 0280)","city":"London","state":"London, City of","zip":"SE1 9RT","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"St Georges University Hospitals NHS Foundation Trust. ( Site 0292)","city":"London","state":"London, City of","zip":"SW17 0QT","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Aberdeen Royal Infirmary ( Site 0288)","city":"Aberdeen","state":"Scotland","zip":"AB25 2ZN","country":"United Kingdom","geoPoint":{"lat":57.14369,"lon":-2.09814}},{"facility":"Leeds Teaching Hospital NHS Trust. St. James University Hospital ( Site 0276)","city":"Leeds","zip":"LS9 7TF","country":"United Kingdom","geoPoint":{"lat":53.79648,"lon":-1.54785}},{"facility":"Leicester Royal Infirmary ( Site 0284)","city":"Leicester","zip":"LE1 5WW","country":"United Kingdom","geoPoint":{"lat":52.6386,"lon":-1.13169}},{"facility":"Christie NHS Foundation Trust ( Site 0275)","city":"Manchester","zip":"M20 4BX","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}},{"facility":"The Clatterbridge Cancer Centre NHS Foundation Trust ( Site 0286)","city":"Metropolitan Borough of Wirral","zip":"CH63 4JY","country":"United Kingdom","geoPoint":{"lat":53.37616,"lon":-3.10501}},{"facility":"Nottingham City Hospital Campus ( Site 0287)","city":"Nottingham","zip":"NG5 1PB","country":"United Kingdom","geoPoint":{"lat":52.9536,"lon":-1.15047}}]},"referencesModule":{"references":[{"pmid":"40419140","type":"RESULT","citation":"Herbst RS, Cho BC, Zhou C, Burotto M, Dols MC, Sendur MAN, Moiseyenko V, Casarini I, Nishio M, Hui R, Pons-Tostivint E, Dudnik J, Ahmed S, Okpara CE, Dutcus C, Yin L, Luo Y, Chirovsky D, Bhagwati N, Abreu DR. Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study. J Thorac Oncol. 2025 Sep;20(9):1302-1314. doi: 10.1016/j.jtho.2025.05.016. Epub 2025 May 24."}],"seeAlsoLinks":[{"label":"Merck Clinical Trials Information","url":"https://www.merckclinicaltrials.com/"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf","url":"http://engagezone.msd.com/ds_documentation.php"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Per protocol, Part 1 participants were excluded from all Part 2 efficacy and safety outcome measures. China participants randomized during the global study phase (134 participants) were included in all global study analyses. China participants randomized during the China extension phase were excluded from all global study analyses and were included in the China-specific analyses in the extension study (NCT04716933).","recruitmentDetails":"Participants with treatment-naïve, metastatic nonsquamous Non-small cell lung cancer (NSCLC) were recruited in this study.","groups":[{"id":"FG000","title":"Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"FG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"FG002","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"375"},{"groupId":"FG002","numSubjects":"373"}]},{"type":"Treated During First Course","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"373"},{"groupId":"FG002","numSubjects":"372"}]},{"type":"Treated During Second Course","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"5"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"375"},{"groupId":"FG002","numSubjects":"373"}]}],"dropWithdraws":[{"type":"Sponsor's Decision","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"90"},{"groupId":"FG002","numSubjects":"102"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"4"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"277"},{"groupId":"FG002","numSubjects":"266"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"BG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"BG002","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"375"},{"groupId":"BG002","value":"373"},{"groupId":"BG003","value":"761"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64.2","spread":"7.6"},{"groupId":"BG001","value":"62.0","spread":"9.9"},{"groupId":"BG002","value":"63.0","spread":"9.7"},{"groupId":"BG003","value":"62.5","spread":"9.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"121"},{"groupId":"BG002","value":"126"},{"groupId":"BG003","value":"253"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"254"},{"groupId":"BG002","value":"247"},{"groupId":"BG003","value":"508"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"77"},{"groupId":"BG003","value":"152"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"291"},{"groupId":"BG002","value":"279"},{"groupId":"BG003","value":"583"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"26"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"116"},{"groupId":"BG002","value":"114"},{"groupId":"BG003","value":"235"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"248"},{"groupId":"BG002","value":"237"},{"groupId":"BG003","value":"493"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"26"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"Randomization of participants in the study was stratified by an ECOG Performance Status of 0 (Fully active, able to carry on all pre-disease performance without restriction) or 1 (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"ECOG = 0","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"135"},{"groupId":"BG002","value":"133"},{"groupId":"BG003","value":"276"}]}]},{"title":"ECOG = 1","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"240"},{"groupId":"BG002","value":"240"},{"groupId":"BG003","value":"485"}]}]}]},{"title":"Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline","description":"Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue from a newly obtained biopsy. Randomization of participants in the study was stratified by PD-L1 tumor proportion score (TPS) at baseline (\\< 50% or ≥ 50%). Higher percentages of PD-L1 TPS staining correspond to higher positivity of PD-L1 on a tumor.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"TPS = < 50%","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"272"},{"groupId":"BG002","value":"269"},{"groupId":"BG003","value":"551"}]}]},{"title":"TPS = ≥ 50%","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"90"},{"groupId":"BG002","value":"91"},{"groupId":"BG003","value":"184"}]}]},{"title":"Not Evaluable","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"26"}]}]}]},{"title":"Geographic Region","description":"Randomization of participants in this study was stratified by geographic region of the enrolling site (East Asia or non-East Asia).","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"East Asia","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"111"},{"groupId":"BG002","value":"112"},{"groupId":"BG003","value":"226"}]}]},{"title":"Non-East Asia","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"264"},{"groupId":"BG002","value":"261"},{"groupId":"BG003","value":"535"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Part 1: Number of Participants With a Dose-limiting Toxicity (DLT)","description":"Dose-limiting toxicity using Common Terminology Criteria for Adverse Events v4.0 for grading, is defined as any of the following hematologic toxicities: 1) Grade 4 neutropenia, 2) Grade 3 or 4 febrile neutropenia, 3) thrombocytopenia \\<25,000 cells/mm\\^3 associated with bleeding and/or which requires platelet transfusion, or any of the following non-hematologic toxicities: 4) any other Grade 4 or 5 toxicity, 5) Grade 3 toxicities lasting \\>3 days (exclusions apply), 6) Grade 3 hypertension not controlled by medication, 7) Grade 3 or above gastrointestinal perforation, 8) Grade 3 or above wound dehiscence requiring medical or surgical intervention, 9) any grade thromboembolic event, or 10) any Grade 3 nonhematologic laboratory value if medical intervention is required or the abnormality leads to hospitalization.","populationDescription":"The analysis population consisted of all participants enrolled in Part 1 who received at least 1 dose of study intervention.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Cycle 1; each cycle is 21 days (up to 21 days)","groups":[{"id":"OG000","title":"Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}]},{"type":"PRIMARY","title":"Part 1: Number of Participants Who Experienced an Adverse Event (AE)","description":"An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one of more adverse events during Part 1 of this study will be presented.","populationDescription":"The analysis population consisted of all participants enrolled in Part 1 who received at least 1 dose of study intervention.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 48 months","groups":[{"id":"OG000","title":"Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}]}]},{"type":"PRIMARY","title":"Part 1: Number of Participants Who Discontinued Study Drug Due to an Adverse Event","description":"An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study medication due to and adverse event during Part 1 of this study will be presented.","populationDescription":"The analysis population consisted of all participants enrolled in Part 1 who received at least 1 dose of study intervention.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 58 months","groups":[{"id":"OG000","title":"Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]}]},{"type":"PRIMARY","title":"Part 2: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"PFS was defined as the time from date of randomization to the date of the first documentation of progressive disease (PD) or death from any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. Data are from the product-limit (Kaplan-Meier) method for censored data. PFS as assessed by blinded independent central review (BICR) per RECIST 1.1 is presented.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least 1 dose of study intervention and were evaluable for response.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 36 months","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"373"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","lowerLimit":"10.4","upperLimit":"14.1"},{"groupId":"OG001","value":"9.5","lowerLimit":"8.3","upperLimit":"10.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparison based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by ECOG performance status (0 versus 1), geographic region of the enrolling site (East Asia versus non-East Asia), and Baseline PD-L1 Status (\\<50% versus \\>=50%).","nonInferiorityType":"OTHER","pValue":"0.07976","statisticalMethod":"Stratified Log Rank","statisticalComment":"Two-sided p-value based on log-rank test stratified by ECOG performance status, geographic region of the enrolling site, and baseline PD-L1 status.","paramType":"Hazard Ratio (HR)","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.74","ciUpperLimit":"1.05"}]},{"type":"PRIMARY","title":"Part 2: Overall Survival (OS)","description":"OS is defined as the time from randomization to the time of death from any cause. OS is presented.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least 1 dose of study intervention and were evaluable for response.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 47 months","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"373"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.8","lowerLimit":"18.6","upperLimit":"24.0"},{"groupId":"OG001","value":"22.1","lowerLimit":"19.7","upperLimit":"24.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparison based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by ECOG performance status (0 versus 1), geographic region of the enrolling site (East Asia versus non-East Asia), and Baseline PD-L1 Status (\\<50% versus \\>=50%).","nonInferiorityType":"OTHER","pValue":"0.70818","statisticalMethod":"Stratified Log Rank","statisticalComment":"Two-sided p-value based on log-rank test stratified by ECOG performance status, geographic region of the enrolling site, and baseline PD-L1 status.","paramType":"Hazard Ratio (HR)","paramValue":"1.05","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.88","ciUpperLimit":"1.26"}]},{"type":"SECONDARY","title":"Part 2: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. ORR as assessed per modified RECIST 1.1 will be presented.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least 1 dose of study intervention and were evaluable for response.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Up to approximately 19 months","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"212"},{"groupId":"OG001","value":"211"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","lowerLimit":"50.1","upperLimit":"63.8"},{"groupId":"OG001","value":"50.7","lowerLimit":"43.8","upperLimit":"57.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparison based on Miettinen \\& Nurminen method stratified by ECOG performance status (0 versus 1), geographic region of the enrolling site (East Asia versus non-East Asia), and Baseline PD-L1 Status (\\<50% versus \\>=50% ).","nonInferiorityType":"OTHER","pValue":"0.08643","statisticalMethod":"Stratified Miettinen & Nurminen","statisticalComment":"One-sided p-value for testing. H0: difference in percent = 0 versus H1: difference in percent \\> 0.","paramType":"Percent Difference","paramValue":"6.3","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.8","ciUpperLimit":"15.4"}]},{"type":"SECONDARY","title":"Part 2: Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)","description":"For participants who demonstrated CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions), DOR is defined as the time from the first documented evidence of CR or PR until PD or death from any cause, whichever occurs first. Per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, or death from any cause, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. DOR as assessed per modified RECIST 1.1 will be presented.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least 1 dose of study intervention and were evaluable for response.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Months","timeFrame":"Up to approximately 48 months","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"373"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"1.1","upperLimit":"15.4"},{"groupId":"OG001","value":"1.6","lowerLimit":"1.2","upperLimit":"20.7"}]}]}]},{"type":"SECONDARY","title":"Part 2: Number of Participants Who Experienced an Adverse Event (AE)","description":"An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced one of more adverse events during Part 2 of this study were presented.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least 1 dose of study intervention.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 58 months","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"373"},{"groupId":"OG001","value":"372"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"372"},{"groupId":"OG001","value":"370"}]}]}]},{"type":"SECONDARY","title":"Part 2: Number of Participants Who Discontinued Study Drug Due to an Adverse Event","description":"An adverse event is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment during Part 2 of this study were presented.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least 1 dose of study intervention.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 58 months","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"373"},{"groupId":"OG001","value":"372"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127"},{"groupId":"OG001","value":"92"}]}]}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in Global Health Status (GHS) (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 [EORTC QLQ-C30] Items 29 and 30) Score","description":"The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions regarding Global Health Status (GHS; \"How would you rate your overall health during the past week?\") and Quality of Life (QoL; \"How would you rate your overall quality of life during the past week?\") are each scored on a 7-point scale (1=Very poor to 7=Excellent). The two raw scores were averaged into a combined score, then normalized using linear transformation so each participant's score ranged from 0 to 100 (0=Worst overall health/quality of life and 100=Best overall health/quality of life). The change from baseline in GHS (EORTC QLQ-C30 Item 29) and QoL (EORTC QLQ-C30 Item 30) combined score is presented","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least one dose of study treatment and have at least one EORTC-QLQ-C30 Items 29 and 30 assessment data available.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Score on a Scale","timeFrame":"Baseline and Week 27","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"369"},{"groupId":"OG001","value":"371"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","lowerLimit":"-1.55","upperLimit":"2.84"},{"groupId":"OG001","value":"1.66","lowerLimit":"-0.53","upperLimit":"3.85"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparision based on a cLDA model with the PRO scores as the response variable with covariates for treatment by time interaction, stratification factors (baseline ECOG performance status (0 versus 1), geographic region of the enrolling site (East Asia versus non-East Asia), and baseline PD-L1 Status ( \\<50% versus ≥50%)) as covariates.","nonInferiorityType":"OTHER","pValue":"0.4805","statisticalMethod":"t-test, 2 sided","paramType":"Difference in Least Square Means","paramValue":"-1.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.83","ciUpperLimit":"1.80"}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in Cough (EORTC Quality of Life Questionnaire-Lung Cancer Module 13 [QLQ-LC13] Item 31) Score","description":"The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question \"How much did you cough?\" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in cough (EORTC QLQ-LC13 Item 31) score will be presented. A lower score indicates a better outcome.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least one dose of study treatment and have at least one EORTC-QLQ-C30 Item 31 assessment data available.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Score on a scale","timeFrame":"Baseline and week 27","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"368"},{"groupId":"OG001","value":"371"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.77","lowerLimit":"-14.72","upperLimit":"-8.81"},{"groupId":"OG001","value":"-11.47","lowerLimit":"-14.42","upperLimit":"-8.53"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparision based on a cLDA model with the PRO scores as the response variable with covariates for treatment by time interaction, stratification factors (baseline ECOG performance status (0 versus 1), geographic region of the enrolling site (East Asia versus non-East Asia), and baseline PD-L1 Status ( \\<50% versus ≥50%)) as covariates.","nonInferiorityType":"OTHER","pValue":"0.8747","statisticalMethod":"t-test, 2 sided","paramType":"Difference in Least Square Means","paramValue":"-0.29","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.95","ciUpperLimit":"3.36"}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in Chest Pain (EORTC QLQ-LC13 Item 40) Score","description":"The EORTC QLQ-LC13 is a lung cancer-specific supplemental questionnaire used in combination with the EORTC QLQ-C30. Participant responses to the question \"Have you had pain in your chest?\" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in chest pain (EORTC QLQ-LC13 Item 40) score will be presented. A lower score indicates a better outcome.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least one dose of study treatment and have at least one EORTC-QLQ-C30 Item 40 assessment data available.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Score on a scale","timeFrame":"Baseline and Week 27","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"368"},{"groupId":"OG001","value":"371"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.61","lowerLimit":"-7.26","upperLimit":"-1.96"},{"groupId":"OG001","value":"-3.70","lowerLimit":"-6.34","upperLimit":"-1.06"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparision based on a cLDA model with the PRO scores as the response variable with covariates for treatment by time interaction, stratification factors (baseline ECOG performance status (0 versus 1), geographic region of the enrolling site (East Asia versus non-East Asia), and baseline PD-L1 Status (\\<50% versus ≥50%)) as covariates.","nonInferiorityType":"OTHER","pValue":"0.5941","statisticalMethod":"t-test, 2 sided","paramType":"Difference in Least Square Means","paramValue":"-0.91","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.24","ciUpperLimit":"2.43"}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in Dyspnea (EORTC QLQ-C30 Item 8) Score","description":"The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the question \"Were you short of breath?\" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in dyspnea (EORTC QLQ-C30 Item 8) score will be presented. A lower score indicates a better outcome.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least one dose of study treatment and have at least one EORTC-QLQ-C30 Item 8 assessment data available.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Score on a scale","timeFrame":"Baseline and Week 27","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"369"},{"groupId":"OG001","value":"371"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.77","lowerLimit":"-6.04","upperLimit":"0.50"},{"groupId":"OG001","value":"-0.61","lowerLimit":"-3.86","upperLimit":"2.65"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparision based on a cLDA model with the PRO scores as the response variable with covariates for treatment by time interaction, stratification factors (baseline ECOG performance status (0 versus 1), geographic region of the enrolling site (East Asia versus non-East Asia), and baseline PD-L1 Status ( \\<50% versus ≥50%)) as covariates.","nonInferiorityType":"OTHER","pValue":"0.3115","statisticalMethod":"t-test, 2 sided","paramType":"covariate","paramValue":"-2.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.36","ciUpperLimit":"2.03"}]},{"type":"SECONDARY","title":"Part 2: Change From Baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) Score","description":"The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score will be presented. A higher score indicates a better quality of life.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least one dose of study treatment and have at least one EORTC-QLQ-C30 Items 1-5 assessment data available.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Score on a scale","timeFrame":"Baseline and Week 27","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"369"},{"groupId":"OG001","value":"371"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.11","lowerLimit":"-6.37","upperLimit":"-1.84"},{"groupId":"OG001","value":"-3.73","lowerLimit":"-5.99","upperLimit":"-1.48"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparision based on a cLDA model with the PRO scores as the response variable with covariates for treatment by time interaction, stratification factors (baseline ECOG performance status (0 versus 1), geographic region of the enrolling site (East Asia versus non-East Asia), and baseline PD-L1 Status ( \\<50% versus ≥50%)) as covariates.","nonInferiorityType":"OTHER","pValue":"0.8134","statisticalMethod":"t-test, 2 sided","paramType":"covariate","paramValue":"-0.37","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.47","ciUpperLimit":"2.72"}]},{"type":"SECONDARY","title":"Part 2: Time to True Deterioration (TTD) Based on Change From Baseline in Global Health Status (GHS)/Quality of Life (QoL) (EORTC QLQ-C30 Items 29 and 30) Score","description":"TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in GHS/QoL (EORTC QLQ-C30 Items 29 and 30) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from Baseline in GHS/QoL score, will be presented. A longer TTD indicates a better outcome.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least one dose of study treatment and have at least one EORTC-QLQ-C30 Items 29 and 30 assessment data available.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline and Week 27","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"358"},{"groupId":"OG001","value":"357"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.70","lowerLimit":"9.66","upperLimit":"NA","comment":"NA=Upper range time to deterioration was not reached at time of data cut-off due to insufficient number of participants experiencing deterioration."},{"groupId":"OG001","value":"NA","lowerLimit":"21.32","upperLimit":"NA","comment":"NA=Median and upper range time to deterioration was not reached at time of data cut-off due to insufficient number of participants experiencing deterioration."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparison based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by ECOG performance status (0 versus 1), geographic region of the enrolling site (East Asia versus non-East Asia), and Baseline PD-L1 Status (\\<50% versus \\>=50%).","nonInferiorityType":"OTHER","pValue":"0.2133","statisticalMethod":"Stratified Log Rank","statisticalComment":"Two-sided p-value based on log-rank test stratified by ECOG performance status, geographic region of the enrolling site, and baseline PD-L1 status.","paramType":"Hazard Ratio (HR)","paramValue":"1.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.92","ciUpperLimit":"1.47"}]},{"type":"SECONDARY","title":"Part 2: TTD Based on Change From Baseline in Cough EORTC QLQ-LC13 (Item 31) Score","description":"TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline cough (EORTC QLQ-LC30 Items 31) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from Baseline in physical functioning score, will be presented. A longer TTD indicates a better outcome.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least one dose of study treatment and have at least one EORTC-QLQ-LC30 Item 31 assessment data available at baseline.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline And Week 27","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"353"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"NA=Median, lower and upper range time to deterioration were not reached at time of data cut-off due to insufficient number of participants experiencing deterioration."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"NA=Median, lower and upper range time to deterioration were not reached at time of data cut-off due to insufficient number of participants experiencing deterioration."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparison based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by ECOG performance status (0 versus 1), geographic region of the enrolling site (East Asia versus non-East Asia), and Baseline PD-L1 Status (\\<50% versus \\>=50%).","nonInferiorityType":"OTHER","pValue":"0.0377","statisticalMethod":"Stratified Log Rank","statisticalComment":"Two-sided p-value based on log-rank test stratified by ECOG performance status, geographic region of the enrolling site, and baseline PD-L1 status.","paramType":"Hazard Ratio (HR)","paramValue":"1.41","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.02","ciUpperLimit":"1.94"}]},{"type":"SECONDARY","title":"Part 2: TTD Based on Change From Baseline in Chest Pain EORTC QLQ-LC13 (Item 40) Score","description":"TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline chest pain (EORTC QLQ-C30 Item 40) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from Baseline in chest pains core, will be presented. A longer TTD indicates a better outcome.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least one dose of study treatment and have at least one EORTC QLQ-LC13 chest pain Item 40 Score assessment data available at baseline.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline and Week 27","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"356"},{"groupId":"OG001","value":"353"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"NA=Median, lower and upper range time to deterioration were not reached at time of data cut-off due to insufficient number of participants experiencing deterioration."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"NA=Median, lower and upper range time to deterioration were not reached at time of data cut-off due to insufficient number of participants experiencing deterioration."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparison based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by ECOG performance status (0 versus 1), geographic region of the enrolling site (East Asia versus non-East Asia), and Baseline PD-L1 Status (\\<50% versus \\>=50%).","nonInferiorityType":"OTHER","pValue":"0.4084","statisticalMethod":"Stratified Log Rank","statisticalComment":"Two-sided p-value based on log-rank test stratified by ECOG performance status, geographic region of the enrolling site, and baseline PD-L1 status.","paramType":"Hazard Ratio (HR)","paramValue":"0.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.62","ciUpperLimit":"1.21"}]},{"type":"SECONDARY","title":"Part 2: TTD Based on Change From Baseline in Dyspnea EORTC QLQ-C30 (Item 8) Score","description":"TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline dyspnea (EORTC QLQ-C30 Item 8) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from Baseline in dyspnea score, will be presented. A longer TTD indicates a better outcome.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least one dose of study treatment and have at least one EORTC-QLQ-C30 Item 8 assessment data available at baseline.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline and Week 27","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"358"},{"groupId":"OG001","value":"357"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"NA=Median, lower and upper range time to deterioration were not reached at time of data cut-off due to insufficient number of participants experiencing deterioration."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"NA=Median, lower and upper range time to deterioration were not reached at time of data cut-off due to insufficient number of participants experiencing deterioration."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparison based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by ECOG performance status (0 versus 1), geographic region of the enrolling site (East Asia versus non-East Asia), and Baseline PD-L1 Status (\\<50% versus \\>=50%).","nonInferiorityType":"OTHER","pValue":"0.7955","statisticalMethod":"Stratified Log Rank","statisticalComment":"Two-sided p-value based on log-rank test stratified by ECOG performance status, geographic region of the enrolling site, and baseline PD-L1 status.","paramType":"Hazard Ratio (HR)","paramValue":"1.04","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.79","ciUpperLimit":"1.36"}]},{"type":"SECONDARY","title":"Part 2: TTD Based on Change From Baseline in Physical Functioning EORTC QLQ-C30 (Items 1 Through 5) Score","description":"TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline physical functioning (EORTC QLQ-C30 Items 1 through 5) score. Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from Baseline in physical functioning score, will be presented. A longer TTD indicates a better outcome.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least one dose of study treatment and have at least one EORTC-QLQ-C30 Items 1 through 5 assessment data available at baseline.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline and Week 27","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"358"},{"groupId":"OG001","value":"357"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.82","lowerLimit":"8.84","upperLimit":"22.51"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"NA=Median, lower and upper range time to deterioration were not reached at time of data cut-off due to insufficient number of participants experiencing deterioration."}]}]}]},{"type":"SECONDARY","title":"Part 2: Time to True Deterioration (TTD) Based on Change From Baseline in the Composite Endpoint of Cough (EORTC QLQ-LC13 Item 31), Chest Pain (EORTC QLQ-LC13 Item 40), or Dyspnea (EORTC QLQ-C30 Item 8)","description":"TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in the composite endpoint of cough (QLQ-LC13 item 31), chest pain (QLQ-LC13 item 40), or dyspnea (QLQ-C30 Item 8). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. The TTD, as assessed based on a ≥10-point negative change (decrease) from Baseline in the composite endpoint of cough, chest pain or dyspnea, will be presented. A longer TTD indicates a better outcome.","populationDescription":"The analysis population consisted of all randomized participants in Part 2 who received at least one dose of study treatment and have at least one EORTC-QLQ-LC13 Items 31 and 40 and EORTC-QLQ-C30 Item 8 assessment data available.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline and Week 27","groups":[{"id":"OG000","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily."},{"id":"OG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"358"},{"groupId":"OG001","value":"358"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.28","lowerLimit":"5.98","upperLimit":"11.07"},{"groupId":"OG001","value":"9.33","lowerLimit":"7.03","upperLimit":"12.91"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Comparison based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by ECOG performance status (0 versus 1), geographic region of the enrolling site (East Asia versus non-East Asia), and Baseline PD-L1 Status (\\<50% versus \\>=50%).","nonInferiorityType":"OTHER","pValue":"0.7191","statisticalMethod":"Stratified Log Rank","statisticalComment":"Two-sided p-value based on log-rank test stratified by ECOG performance status, geographic region of the enrolling site, and baseline PD-L1 status.","paramType":"Hazard Ratio (HR)","paramValue":"1.04","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.84","ciUpperLimit":"1.28"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to approximately 58 months","description":"All-cause mortality was reported on all randomized participants (first and second course). Serious and non-serious AEs were reported among participants who received at least one dose of study treatment. MedDRA preferred terms 'Neoplasm progression', 'Malignant neoplasm progression' and 'Disease progression' not related to the drug were excluded. AEs occurring during second course treatment were collected and presented separately from those occurring during the initial treatment.","eventGroups":[{"id":"EG000","title":"Part 1 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily.","deathsNumAffected":9,"deathsNumAtRisk":13,"seriousNumAffected":7,"seriousNumAtRisk":13,"otherNumAffected":13,"otherNumAtRisk":13},{"id":"EG001","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Participants received carboplatin Area Under Curve 5 mg/mL/min (AUC5) or cisplatin 75 mg/m\\^2 via intravenous (IV) infusion on Day 1 of each 3-week cycle (Q3W) for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS lenvatinib 8 mg via oral capsule once daily.","deathsNumAffected":278,"deathsNumAtRisk":375,"seriousNumAffected":232,"seriousNumAtRisk":373,"otherNumAffected":366,"otherNumAtRisk":373},{"id":"EG002","title":"Part 2 First Course: Pembrolizumab+Chemotherapy+Placebo","description":"Participants received carboplatin AUC5 or cisplatin 75 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pemetrexed 500 mg/m\\^2 via IV infusion Q3W for 4 cycles PLUS pembrolizumab 200 mg via IV infusion Q3W for up to 35 cycles (up to 2 years) PLUS placebo matching lenvatinib via oral capsule once daily.","deathsNumAffected":266,"deathsNumAtRisk":373,"seriousNumAffected":189,"seriousNumAtRisk":372,"otherNumAffected":363,"otherNumAtRisk":372},{"id":"EG003","title":"Part 1 Second Course: Pembrolizumab Only From Pembrolizumab+Chemotherapy+Lenvatinib","description":"Qualified participants who completed the first course of pembrolizumab plus chemotherapy plus lenvatinib for up to 35 cycles (up to 2 years), but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q2W for up to \\~1 year, without chemotherapy plus lenvatinib.","deathsNumAffected":0,"deathsNumAtRisk":1,"seriousNumAffected":1,"seriousNumAtRisk":1,"otherNumAffected":1,"otherNumAtRisk":1},{"id":"EG004","title":"Part 2 Second Course: Pembrolizumab+Chemotherapy+Lenvatinib","description":"Qualified participants who completed the first course of pembrolizumab plus chemotherapy plus lenvatinib for up to 35 cycles (up to 2 years), but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q2W for up to \\~1 year. Participants previously receiving Lenvatinib could continue receiving lenvatinib at investigator's discretion.","deathsNumAffected":3,"deathsNumAtRisk":3,"seriousNumAffected":1,"seriousNumAtRisk":3,"otherNumAffected":2,"otherNumAtRisk":3},{"id":"EG005","title":"Part 2 Second Course: Pembrolizumab+Chemotherapy+Placebo","description":"Qualified participants who completed the first course of pembrolizumab plus chemotherapy plus lenvatinib for up to 35 cycles (up to 2 years), but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q2W for up to \\~1 year. Participants previously receiving placebo could continue receiving placebo at investigator's discretion.","deathsNumAffected":3,"deathsNumAtRisk":7,"seriousNumAffected":3,"seriousNumAtRisk":7,"otherNumAffected":4,"otherNumAtRisk":7}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":19,"numAffected":17,"numAtRisk":373},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Bone marrow failure","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":373},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Spontaneous haematoma","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Acute coronary syndrome","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Atrial thrombosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cardiac tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cardio-respiratory arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Immune-mediated myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Vertigo positional","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Adrenal haematoma","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypophysitis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Vitreous haemorrhage","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Anal fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Coeliac artery stenosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":373},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Duodenitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Enteritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Faecaloma","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastric ulcer haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastrointestinal inflammation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Inguinal hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Neutropenic colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Obstruction gastric","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pancreatitis acute","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Proctitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Subileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":373},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":373},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hepatic cirrhosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hepatic cytolysis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hepatic haematoma","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Perforation bile duct","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Abdominal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Anorectal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Biliary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Bronchitis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":373},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":373},{"groupId":"EG002","numEvents":10,"numAffected":10,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Campylobacter gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Catheter site infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Encephalitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Erysipelas","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Febrile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Myelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Osteomyelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Parainfluenzae virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Peritonsillar abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pneumocystis jirovecii pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":37,"numAffected":28,"numAtRisk":373},{"groupId":"EG002","numEvents":40,"numAffected":36,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Pneumonia aspiration","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pneumonia fungal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pneumonia klebsiella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pyelonephritis acute","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":373},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Varicella zoster virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Foot fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Procedural pneumothorax","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Synovial rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tendon rupture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Toxicity to various agents","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tracheal haemorrhage","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":373},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"SARS-CoV-2 test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":372},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Osteonecrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Osteonecrosis of jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Rotator cuff syndrome","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Breast cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Invasive ductal breast carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Liposarcoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tumour associated fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Basal ganglia infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cerebral thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":373},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Haemorrhagic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Immune-mediated encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Intracranial aneurysm","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Ischaemic cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sensory disturbance","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Spondylitic myelopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Device dislocation","organSystem":"Product Issues","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Behaviour disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Disorientation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":373},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Autoimmune nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Immune-mediated nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Nephropathy","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tubulointerstitial nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Urinary tract obstruction","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Bronchopneumopathy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Emphysema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":373},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hydrothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Immune-mediated lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Lung infiltration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pharyngeal haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":373},{"groupId":"EG002","numEvents":10,"numAffected":9,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":373},{"groupId":"EG002","numEvents":16,"numAffected":15,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pneumothorax spontaneous","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pulmonary artery thrombosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":373},{"groupId":"EG002","numEvents":8,"numAffected":8,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Pulmonary fibrosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pulmonary infarction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Respiratory arrest","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dermatitis herpetiformis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pseudocellulitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Superficial inflammatory dermatosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Arterial disorder","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Arterial thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Jugular vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Peripheral artery thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Venous thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Arteriosclerosis coronary artery","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Ulcerative keratitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Soft tissue infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Subdural haematoma","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Type 2 diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":394,"numAffected":192,"numAtRisk":373},{"groupId":"EG002","numEvents":419,"numAffected":220,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":9,"numAffected":4,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":373},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":30,"numAffected":26,"numAtRisk":373},{"groupId":"EG002","numEvents":27,"numAffected":23,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":13},{"groupId":"EG001","numEvents":104,"numAffected":84,"numAtRisk":373},{"groupId":"EG002","numEvents":46,"numAffected":42,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Thyroid mass","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":373},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":373},{"groupId":"EG002","numEvents":14,"numAffected":14,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Eye pain","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Eye pruritus","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":373},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Glaucoma","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":25,"numAffected":24,"numAtRisk":373},{"groupId":"EG002","numEvents":28,"numAffected":24,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":373},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":47,"numAffected":33,"numAtRisk":373},{"groupId":"EG002","numEvents":27,"numAffected":20,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":33,"numAffected":30,"numAtRisk":373},{"groupId":"EG002","numEvents":20,"numAffected":18,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Anal incontinence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":13},{"groupId":"EG001","numEvents":169,"numAffected":120,"numAtRisk":373},{"groupId":"EG002","numEvents":143,"numAffected":110,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":13},{"groupId":"EG001","numEvents":245,"numAffected":127,"numAtRisk":373},{"groupId":"EG002","numEvents":107,"numAffected":69,"numAtRisk":372},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":373},{"groupId":"EG002","numEvents":12,"numAffected":10,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":25,"numAffected":23,"numAtRisk":373},{"groupId":"EG002","numEvents":11,"numAffected":11,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":14,"numAffected":13,"numAtRisk":373},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastrointestinal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gingival bleeding","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gingival pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":15,"numAffected":11,"numAtRisk":373},{"groupId":"EG002","numEvents":6,"numAffected":3,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Glossodynia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Lip dry","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":10,"numAtRisk":13},{"groupId":"EG001","numEvents":264,"numAffected":148,"numAtRisk":373},{"groupId":"EG002","numEvents":246,"numAffected":137,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":373},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Rectal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":64,"numAffected":47,"numAtRisk":373},{"groupId":"EG002","numEvents":30,"numAffected":21,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":17,"numAffected":13,"numAtRisk":373},{"groupId":"EG002","numEvents":10,"numAffected":7,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":13},{"groupId":"EG001","numEvents":133,"numAffected":69,"numAtRisk":373},{"groupId":"EG002","numEvents":99,"numAffected":62,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":167,"numAffected":108,"numAtRisk":373},{"groupId":"EG002","numEvents":175,"numAffected":110,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":23,"numAffected":21,"numAtRisk":373},{"groupId":"EG002","numEvents":29,"numAffected":25,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Extravasation","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":8,"numAtRisk":13},{"groupId":"EG001","numEvents":182,"numAffected":116,"numAtRisk":373},{"groupId":"EG002","numEvents":114,"numAffected":86,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":11,"numAffected":7,"numAtRisk":373},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":24,"numAffected":15,"numAtRisk":373},{"groupId":"EG002","numEvents":18,"numAffected":15,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":62,"numAffected":47,"numAtRisk":373},{"groupId":"EG002","numEvents":35,"numAffected":28,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":373},{"groupId":"EG002","numEvents":13,"numAffected":9,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":373},{"groupId":"EG002","numEvents":11,"numAffected":9,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":81,"numAffected":61,"numAtRisk":373},{"groupId":"EG002","numEvents":70,"numAffected":49,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":373},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":98,"numAffected":57,"numAtRisk":373},{"groupId":"EG002","numEvents":83,"numAffected":61,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":32,"numAffected":32,"numAtRisk":373},{"groupId":"EG002","numEvents":24,"numAffected":23,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":27,"numAffected":24,"numAtRisk":373},{"groupId":"EG002","numEvents":21,"numAffected":18,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Eye infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Fungal skin infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":373},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":13,"numAffected":10,"numAtRisk":373},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":373},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Oral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Otitis externa","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":27,"numAffected":23,"numAtRisk":373},{"groupId":"EG002","numEvents":22,"numAffected":21,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":31,"numAffected":22,"numAtRisk":373},{"groupId":"EG002","numEvents":21,"numAffected":15,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":5,"numAtRisk":13},{"groupId":"EG001","numEvents":41,"numAffected":30,"numAtRisk":373},{"groupId":"EG002","numEvents":35,"numAffected":29,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Viral pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":373},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Ligament injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":271,"numAffected":132,"numAtRisk":373},{"groupId":"EG002","numEvents":251,"numAffected":119,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":108,"numAffected":55,"numAtRisk":373},{"groupId":"EG002","numEvents":95,"numAffected":55,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":311,"numAffected":127,"numAtRisk":373},{"groupId":"EG002","numEvents":240,"numAffected":108,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":52,"numAffected":31,"numAtRisk":373},{"groupId":"EG002","numEvents":44,"numAffected":31,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":31,"numAffected":20,"numAtRisk":373},{"groupId":"EG002","numEvents":18,"numAffected":9,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":13},{"groupId":"EG001","numEvents":122,"numAffected":66,"numAtRisk":373},{"groupId":"EG002","numEvents":104,"numAffected":69,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":31,"numAffected":21,"numAtRisk":373},{"groupId":"EG002","numEvents":28,"numAffected":22,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Blood magnesium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":31,"numAffected":23,"numAtRisk":373},{"groupId":"EG002","numEvents":29,"numAffected":17,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":51,"numAffected":38,"numAtRisk":373},{"groupId":"EG002","numEvents":12,"numAffected":9,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":73,"numAffected":49,"numAtRisk":373},{"groupId":"EG002","numEvents":39,"numAffected":30,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Lactescent serum","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":94,"numAffected":47,"numAtRisk":373},{"groupId":"EG002","numEvents":82,"numAffected":43,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":54,"numAffected":29,"numAtRisk":373},{"groupId":"EG002","numEvents":31,"numAffected":18,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":13},{"groupId":"EG001","numEvents":526,"numAffected":188,"numAtRisk":373},{"groupId":"EG002","numEvents":436,"numAffected":154,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":348,"numAffected":148,"numAtRisk":373},{"groupId":"EG002","numEvents":203,"numAffected":98,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"SARS-CoV-2 test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":373},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":82,"numAffected":69,"numAtRisk":373},{"groupId":"EG002","numEvents":31,"numAffected":29,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":30,"numAffected":20,"numAtRisk":373},{"groupId":"EG002","numEvents":8,"numAffected":7,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":372,"numAffected":119,"numAtRisk":373},{"groupId":"EG002","numEvents":306,"numAffected":95,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":218,"numAffected":130,"numAtRisk":373},{"groupId":"EG002","numEvents":150,"numAffected":112,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":373},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":69,"numAffected":39,"numAtRisk":373},{"groupId":"EG002","numEvents":56,"numAffected":33,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":28,"numAffected":20,"numAtRisk":373},{"groupId":"EG002","numEvents":26,"numAffected":19,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":81,"numAffected":39,"numAtRisk":373},{"groupId":"EG002","numEvents":51,"numAffected":28,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":26,"numAffected":19,"numAtRisk":373},{"groupId":"EG002","numEvents":22,"numAffected":18,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":59,"numAffected":39,"numAtRisk":373},{"groupId":"EG002","numEvents":41,"numAffected":27,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":59,"numAffected":36,"numAtRisk":373},{"groupId":"EG002","numEvents":42,"numAffected":29,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":72,"numAffected":44,"numAtRisk":373},{"groupId":"EG002","numEvents":64,"numAffected":31,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":72,"numAffected":54,"numAtRisk":373},{"groupId":"EG002","numEvents":38,"numAffected":33,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":6,"numAtRisk":13},{"groupId":"EG001","numEvents":52,"numAffected":44,"numAtRisk":373},{"groupId":"EG002","numEvents":47,"numAffected":42,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":20,"numAffected":19,"numAtRisk":373},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":21,"numAffected":20,"numAtRisk":373},{"groupId":"EG002","numEvents":19,"numAffected":16,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":43,"numAffected":32,"numAtRisk":373},{"groupId":"EG002","numEvents":18,"numAffected":17,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":50,"numAffected":39,"numAtRisk":373},{"groupId":"EG002","numEvents":42,"numAffected":36,"numAtRisk":372},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dizziness postural","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13},{"groupId":"EG001","numEvents":28,"numAffected":26,"numAtRisk":373},{"groupId":"EG002","numEvents":22,"numAffected":19,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Encephalitis autoimmune","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":64,"numAffected":45,"numAtRisk":373},{"groupId":"EG002","numEvents":44,"numAffected":35,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":373},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":23,"numAffected":20,"numAtRisk":373},{"groupId":"EG002","numEvents":19,"numAffected":18,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":373},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Post herpetic neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Vocal cord paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":373},{"groupId":"EG002","numEvents":12,"numAffected":9,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":28,"numAffected":26,"numAtRisk":373},{"groupId":"EG002","numEvents":43,"numAffected":32,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":373},{"groupId":"EG002","numEvents":10,"numAffected":9,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":114,"numAffected":55,"numAtRisk":373},{"groupId":"EG002","numEvents":37,"numAffected":26,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Breast pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Erectile dysfunction","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pelvic pain","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":373},{"groupId":"EG002","numEvents":4,"numAffected":2,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":13},{"groupId":"EG001","numEvents":82,"numAffected":65,"numAtRisk":373},{"groupId":"EG002","numEvents":60,"numAffected":50,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":36,"numAffected":31,"numAtRisk":373},{"groupId":"EG002","numEvents":12,"numAffected":12,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":78,"numAffected":63,"numAtRisk":373},{"groupId":"EG002","numEvents":68,"numAffected":66,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":373},{"groupId":"EG002","numEvents":7,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":86,"numAffected":55,"numAtRisk":373},{"groupId":"EG002","numEvents":21,"numAffected":17,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":23,"numAffected":20,"numAtRisk":373},{"groupId":"EG002","numEvents":20,"numAffected":14,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":4,"numAtRisk":13},{"groupId":"EG001","numEvents":21,"numAffected":18,"numAtRisk":373},{"groupId":"EG002","numEvents":30,"numAffected":21,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Immune-mediated lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":21,"numAffected":20,"numAtRisk":373},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":373},{"groupId":"EG002","numEvents":22,"numAffected":22,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":19,"numAffected":15,"numAtRisk":373},{"groupId":"EG002","numEvents":25,"numAffected":23,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":14,"numAffected":11,"numAtRisk":373},{"groupId":"EG002","numEvents":12,"numAffected":11,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":19,"numAffected":16,"numAtRisk":373},{"groupId":"EG002","numEvents":15,"numAffected":15,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Decubitus ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":13},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":373},{"groupId":"EG002","numEvents":14,"numAffected":13,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pain of skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":13},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":373},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":13},{"groupId":"EG001","numEvents":56,"numAffected":45,"numAtRisk":373},{"groupId":"EG002","numEvents":68,"numAffected":48,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":13},{"groupId":"EG001","numEvents":86,"numAffected":64,"numAtRisk":373},{"groupId":"EG002","numEvents":64,"numAffected":57,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Rash vesicular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Skin lesion","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":373},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":373},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":9,"numAtRisk":13},{"groupId":"EG001","numEvents":158,"numAffected":110,"numAtRisk":373},{"groupId":"EG002","numEvents":46,"numAffected":44,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Degenerative aortic valve disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":13},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":373},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":373},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":18,"numAffected":13,"numAtRisk":373},{"groupId":"EG002","numEvents":21,"numAffected":12,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]},{"term":"Urinary occult blood positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":373},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":373},{"groupId":"EG002","numEvents":20,"numAffected":9,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":7}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 26.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":13},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":373},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":372},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":1},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":7}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.\n\nAny information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme LLC","email":"ClinicalTrialsDisclosure@msd.com","phone":"1-800-672-6372"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2023-10-27","uploadDate":"2025-08-20T15:05","filename":"Prot_SAP_001.pdf","size":1542290}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-09-04","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"C565324","term":"Parkinson Disease 4, Autosomal Dominant Lewy Body"}]},"interventionBrowseModule":{"meshes":[{"id":"C582435","term":"pembrolizumab"},{"id":"D016190","term":"Carboplatin"},{"id":"D002945","term":"Cisplatin"},{"id":"D000068437","term":"Pemetrexed"},{"id":"C531958","term":"lenvatinib"}],"ancestors":[{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}